Three things to know:
1. Since 2015, Dr. Caforio has served as CEO of biopharmaceutical company Bristol Myers Squibb. He assumed the role of chairman of the board in 2017.
2. He has led Bristol Myers Squibb’s research and development transformational medicines, which include products for oncology, hematology, immunology and cardiovascular disease.
3. Dr. Caforio is chairman of the Pharmaceutical Research and Manufacturers of America, a trade association representing pharmaceutical companies in the U.S.
More articles on devices:
Robotics in spine surgery: 17 notes for surgeons, ASCs & administrators
Zimmer Biomet net sales increase 2%, knee sales dip .5% in Q3
10 most influential orthopedic specialists on Twitter in Q3, according to GlobalData
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
